Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

44.420
-1.180-2.59%
Volume:1.94M
Turnover:86.59M
Market Cap:294.82B
PE:32.16
High:45.500
Open:45.500
Low:44.240
Close:45.600
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.52
T/O Rate:0.75%
Dividend:0.23
Dividend Rate:0.53%
EPS(LYR):1.381
ROE:12.46%
ROA:7.02%
PB:3.91
PE(LYR):32.16
PS:8.04

Loading ...

The Capital Group Companies Increases Stake in Hengrui Pharma with 483,600 Share Purchase at Approximately HK$57.90 Each

Deep News
·
Aug 03

AH Share Premium Rankings for July 31

Stock News
·
Jul 31

AH Share Premium Ranking Update: July 30 Market Close

Stock News
·
Jul 30

Movement Alert|HENGRUI PHARMA Falls 3.17% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure Despite Multiple Positive Catalysts

Market Focus
·
Jul 30

Hengrui Pharma Wins China Regulator's Nod for Three Drugs

MT Newswires Live
·
Jul 30

Capital Group Boosts Stake in Hengrui Pharma with 752,200 Share Purchase

Deep News
·
Jul 30

Hengrui Pharma Secures NMPA Nod for China’s First Home-grown Long-Acting Insulin Analog

Bulletin Express
·
Jul 29

Hengrui Pharma's Self-Developed Class 1 Biologic Insulin Analogue Receives Market Approval

Stock News
·
Jul 29

Jiangsu Hengrui Receives Approval for China's First Self-Developed Long-Acting Insulin Analog

Stock News
·
Jul 29

Market Highlights: First Domestically Developed Long-Acting Diabetes Treatment Approved, Hengrui Pharma Leads

Stock News
·
Jul 29

Hengrui Pharma's Recombinant Anti-Tumor Antibody Injection Receives NMPA Approval Application Submission

Stock News
·
Jul 29

AH Premium Data Overview: July 29 Market Close

Stock News
·
Jul 29

AH Share Premium and Discount Report for July 28

Stock News
·
Jul 28

Jiangsu Hengrui Pharmaceuticals Gets China Nod for Hypertension Drug Trial

MT Newswires Live
·
Jul 28

Hengrui Pharmaceuticals' Pancreatic Cancer Drug Gets US FDA Orphan Status

MT Newswires Live
·
Jul 28

Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy

MT Newswires Live
·
Jul 27

Citigroup’s Short Position in H-shares of Jiangsu Hengrui Pharmaceuticals Decreases to 2.53% on July 20 from 3.07% - HKEX Filing

THOMSON REUTERS
·
Jul 24

Cross-Listed Stock Premium Report: Closing Data for July 24

Stock News
·
Jul 24

Hengrui Pharma gains NMPA approval for camrelizumab-famitinib as first-line treatment in recurrent/metastatic cervical cancer

Bulletin Express
·
Jul 23

AH Share Premium and Deviation Data for July 22nd

Stock News
·
Jul 22